JP2013544781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544781A5 JP2013544781A5 JP2013533102A JP2013533102A JP2013544781A5 JP 2013544781 A5 JP2013544781 A5 JP 2013544781A5 JP 2013533102 A JP2013533102 A JP 2013533102A JP 2013533102 A JP2013533102 A JP 2013533102A JP 2013544781 A5 JP2013544781 A5 JP 2013544781A5
- Authority
- JP
- Japan
- Prior art keywords
- nasal
- nose
- carrier material
- powder
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010048374A DE102010048374A1 (de) | 2010-10-13 | 2010-10-13 | Pyrrolidinone als MetAP-2 Inhibitoren |
| DE102010048374.5 | 2010-10-13 | ||
| PCT/EP2011/004608 WO2012048775A1 (de) | 2010-10-13 | 2011-09-14 | Pyrrolidinone als metap-2 inhibitoren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544781A JP2013544781A (ja) | 2013-12-19 |
| JP2013544781A5 true JP2013544781A5 (https=) | 2016-02-25 |
| JP5931885B2 JP5931885B2 (ja) | 2016-06-08 |
Family
ID=44677838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013533102A Active JP5931885B2 (ja) | 2010-10-13 | 2011-09-14 | ＭｅｔＡＰ２阻害剤としてのピロリジノン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8895535B2 (https=) |
| EP (1) | EP2627631B1 (https=) |
| JP (1) | JP5931885B2 (https=) |
| KR (1) | KR101803126B1 (https=) |
| CN (1) | CN103153951B (https=) |
| AR (1) | AR083402A1 (https=) |
| AU (1) | AU2011316199B2 (https=) |
| BR (1) | BR112013008886B1 (https=) |
| CA (1) | CA2814369C (https=) |
| CY (1) | CY1117287T1 (https=) |
| DE (1) | DE102010048374A1 (https=) |
| DK (1) | DK2627631T3 (https=) |
| EA (1) | EA022299B1 (https=) |
| ES (1) | ES2563317T3 (https=) |
| HR (1) | HRP20160249T1 (https=) |
| HU (1) | HUE027149T2 (https=) |
| IL (1) | IL225626A0 (https=) |
| MX (1) | MX2013004004A (https=) |
| PL (1) | PL2627631T3 (https=) |
| RS (1) | RS54629B1 (https=) |
| SG (1) | SG189853A1 (https=) |
| SI (1) | SI2627631T1 (https=) |
| WO (1) | WO2012048775A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8575349B2 (en) * | 2010-11-22 | 2013-11-05 | International Flavors & Fragrances Inc. | Derivatives of 1-alkyl-6-oxo-piperidine-3-carboxylic acids and 1-alkyl-5-oxo-pyrrolidine-3-carboxylic acids and their uses as cooling compounds |
| PT2573073E (pt) * | 2011-09-26 | 2015-02-05 | Sanofi Sa | Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica |
| JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| DE102012006884A1 (de) * | 2012-04-04 | 2013-10-10 | Merck Patent Gmbh | Cyclische Amide als MetAP-2 Inhibitoren |
| EP3045448A4 (en) * | 2013-09-12 | 2017-01-25 | Sumitomo Chemical Company Limited | Nitrogen-containing saturated heterocyclic compound |
| JP6619420B2 (ja) * | 2014-08-04 | 2019-12-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｍｅｔａｐ−２阻害剤としてのピロリジノン誘導体 |
| WO2017084096A1 (en) * | 2015-11-20 | 2017-05-26 | Eli Lilly And Company | Pyrrolidinone compounds |
| WO2017004797A1 (en) * | 2015-07-08 | 2017-01-12 | Eli Lilly And Company | Pyrrolidinone compounds |
| AU2017280099A1 (en) * | 2016-06-21 | 2019-01-17 | The University Of Melbourne | Activators of HIV latency |
| WO2018098781A1 (en) * | 2016-12-01 | 2018-06-07 | Eli Lilly And Company | Pyrrolidinone compounds |
| US11365194B2 (en) * | 2017-09-27 | 2022-06-21 | Kagoshima University | Analgesic drug using PAC1 receptor antagonistic drug |
| CN108409630B (zh) * | 2018-02-07 | 2021-01-15 | 宁波大学 | 一种水相中3-羟基-2-吲哚酮衍生物的制备方法 |
| ES2934986T3 (es) * | 2019-01-22 | 2023-02-28 | Merck Patent Gmbh | Derivados heterocíclicos |
| SI3994134T1 (sl) | 2019-07-03 | 2024-06-28 | Merck Patent Gmbh | Postopek za izdelavo (s)-3-hidroksi-1-(1h-indol-5-il)-2-okso-pirolidin-3-karboksilne kisline 3,5-difluoro-benzilamida |
| CN112480100B (zh) * | 2019-09-11 | 2022-10-14 | 康威(广州)生物科技有限公司 | 吡咯烷酮衍生物 |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN115989027A (zh) | 2020-07-09 | 2023-04-18 | 默克专利股份公司 | 甲硫氨酸氨肽酶2抑制剂和vegfr/vegf抑制剂的组合 |
| CN112851561A (zh) * | 2021-01-29 | 2021-05-28 | 南京艾美斐生物医药科技有限公司 | 一种nr6a1蛋白受体抑制剂及其制备和应用 |
| KR20230170693A (ko) * | 2021-03-28 | 2023-12-19 | 캔웰 바이오테크 리미티드 | Metap-2 억제제, 약제학적 조성물 및 이의 치료 방법 |
| WO2023144053A1 (en) | 2022-01-26 | 2023-08-03 | Merck Patent Gmbh | Heterocyclic derivatives |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| AR028537A1 (es) | 2000-04-14 | 2003-05-14 | Abbott Lab | Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis |
| US20070161570A1 (en) | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| AU2002306907A1 (en) | 2001-04-03 | 2002-10-21 | Smithkline Beecham Corporation | Method for inhibiting metap2 |
| US20030225054A1 (en) * | 2002-06-03 | 2003-12-04 | Jingwu Duan | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents |
| AU2003274037A1 (en) | 2002-10-18 | 2004-05-13 | Basf Aktiengesellschaft | 1-phenylpyrrolidine-2-one-3-carboxamides |
| JP2006104280A (ja) | 2004-10-04 | 2006-04-20 | Toyo Tire & Rubber Co Ltd | 高熱伝導性加硫ゴム成形体及びダイアフラム |
| US20090264650A1 (en) | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
| US20070123508A1 (en) | 2005-05-27 | 2007-05-31 | Roger Olsson | PAR2-modulating compounds and their use |
| UY31984A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
| BR112012016793A2 (pt) | 2010-01-08 | 2018-07-31 | Zafgen Corp | compostos tipo fumagilol e métodos de fazer e usar os mesmos |
-
2010
- 2010-10-13 DE DE102010048374A patent/DE102010048374A1/de not_active Withdrawn
-
2011
- 2011-09-14 SG SG2013026133A patent/SG189853A1/en unknown
- 2011-09-14 CA CA2814369A patent/CA2814369C/en active Active
- 2011-09-14 ES ES11761005T patent/ES2563317T3/es active Active
- 2011-09-14 EA EA201300442A patent/EA022299B1/ru not_active IP Right Cessation
- 2011-09-14 CN CN201180049753.6A patent/CN103153951B/zh active Active
- 2011-09-14 AU AU2011316199A patent/AU2011316199B2/en active Active
- 2011-09-14 HR HRP20160249TT patent/HRP20160249T1/hr unknown
- 2011-09-14 SI SI201130753T patent/SI2627631T1/sl unknown
- 2011-09-14 KR KR1020137011998A patent/KR101803126B1/ko active Active
- 2011-09-14 MX MX2013004004A patent/MX2013004004A/es unknown
- 2011-09-14 EP EP11761005.5A patent/EP2627631B1/de active Active
- 2011-09-14 BR BR112013008886-9A patent/BR112013008886B1/pt active IP Right Grant
- 2011-09-14 HU HUE11761005A patent/HUE027149T2/en unknown
- 2011-09-14 US US13/878,574 patent/US8895535B2/en active Active
- 2011-09-14 DK DK11761005.5T patent/DK2627631T3/en active
- 2011-09-14 WO PCT/EP2011/004608 patent/WO2012048775A1/de not_active Ceased
- 2011-09-14 RS RS20160123A patent/RS54629B1/sr unknown
- 2011-09-14 PL PL11761005T patent/PL2627631T3/pl unknown
- 2011-09-14 JP JP2013533102A patent/JP5931885B2/ja active Active
- 2011-10-13 AR ARP110103781A patent/AR083402A1/es not_active Application Discontinuation
-
2013
- 2013-04-08 IL IL225626A patent/IL225626A0/en active IP Right Grant
-
2016
- 2016-03-15 CY CY20161100221T patent/CY1117287T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544781A5 (https=) | ||
| JP2014526447A5 (https=) | ||
| JP2013534227A5 (https=) | ||
| JP2014509313A5 (https=) | ||
| JP2015505541A5 (https=) | ||
| JP2013541565A5 (https=) | ||
| Weber et al. | Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art | |
| BR112013022249B8 (pt) | Dispositivo de distribuição de droga nasal | |
| WO2014074797A8 (en) | Ultra low density pulmonary powders | |
| WO2013155201A3 (en) | Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration | |
| EA201590286A1 (ru) | Аэрозольное ингаляционное устройство | |
| CL2013000958A1 (es) | Dispositivo atomizador nasal para la administracion de una formulacion farmaceutica a traves de la cavidad nasal en dosis controladas, comprende: un cartucho de aerosol presurizado que a su vez incluye un frasco con una formulacion farmaceutica, el accionador comprende una salida de administracion para el penacho de aerosol, donde el orificio de descarga se encuentra dispuesto de manera de dirigir el penacho de aerosol a traves de la salida de administracion; uso. | |
| TN2015000395A1 (en) | Respirable agglomerates of porous carrier particles and micronized drug | |
| JP2013538214A5 (https=) | ||
| CL2013000153A1 (es) | Metodo para entregar una solucion de un medicamento a un ojo de un sujeto que lo necesita, comprende, el proveer gotitas que contienen dicho medicamento, en donde dichas gotitas tienen un tamaño promedio de gotita por lo menos de aproximadamente 15 micrones y una velocidad de eyeccion inicial promedio entre 1 m/s y 5 m/s, y entregar dicho medicamento a dicho ojo, donde entre aproximadamente 80% y 100% de la masa de dichas gotitas es depositado en el ojo. | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| WO2013038267A8 (en) | Tamper resistant pharmaceutical formulations | |
| JP2014530231A5 (https=) | ||
| EA201401354A1 (ru) | Новая дозированная форма и препарат, содержащий абедитерол | |
| WO2013038268A8 (en) | Tamper resistant immediate release formulations | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| WO2012047182A3 (en) | Single dose dry powder inhalation device | |
| EP4233874A3 (en) | Acetylsalicylic acid for reducing the risk of a thromboembolic event | |
| EA201700182A1 (ru) | Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой |